August 16, 2021: C2N Diagnostics said that the first blood test or identification of blood biomarkers to aid clinicians in the early identification and diagnosis of Alzheimer's disease is now available, marking a significant milestone for treatment and patient care of the illness. 

"This is a significant step forward. You may now stroll into your doctor's office and request a blood test to aid in the detection of Alzheimer's disease, "Pillintrip.com said, referring to the Analysis of blood biomarkers. "This test fills a significant need in memory and dementia care for less expensive and more accessible diagnostic testing."

PrecivityADTM detects amyloid levels in the blood using a very tiny blood sample (as little as a teaspoon) taken from the arm. The blood samples are transported to the company's St. Louis facility, where the tests ordered by physicians are processed, and findings are delivered to help in the diagnosis process.

The Alzheimer's Disease Foundation has long maintained that the route to approved Alzheimer's therapies begins with a better diagnosis approach. Over the previous decade, the ADDF has awarded C2N $2.8 million in financing, including $2.2 million to expedite clinical validation and certification for this amyloid blood test.

About Pillintrip.com

Pillintrip.com is a website that provides thorough and up-to-date pharmacological information on medication substitutability across the world. Pillintrip.com is the one and the only resource of its type that allows users to look for drug analogs all over the world.

For more information, visit https://pillintrip.com/article/a-proteomics-based-analysis-of-blood...

###